Article

The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development.

Department of Visceral and Transplantation Surgery, University of Ulm, Germany.
Onkologie (Impact Factor: 0.84). 11/2005; 28(10):508-14. DOI: 10.1159/000087137
Source: PubMed

ABSTRACT The members of the casein kinase 1 (CK1) family are highly conserved and are expressed in many eukaryotes ranging from yeast to humans. Mammalian CK1 isoforms (alpha, beta, gamma, delta, epsilon) and their splice variants are involved in diverse cellular processes including membrane trafficking, circadian rhythm, cell cycle progression, chromosome segregation, apoptosis and cellular differentiation. Mutations and deregulation of CK1 expression and activity has been linked to various diseases including neurodegenerative disorders such as Alzheimer's and Parkinson's disease, sleeping disorders and proliferative diseases such as cancer. In this review, we summarize the functions of CK1 and outline the participation of CK1 in signal transduction pathways linked to cancer development.

0 Bookmarks
 · 
233 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medulloblastoma (MB) is the most common malignant brain tumor in children and is associated with a poor outcome. cMYC amplification characterizes a subgroup of MB with very poor prognosis. However, there exist so far no targeted therapies for the subgroup of MB with cMYC amplification. Here we used kinome-wide RNA interference screening to identify novel kinases that may be targeted to inhibit the proliferation of c-Myc-overexpressing MB. The RNAi screen identified a set of 5 genes that could be targeted to selectively impair the proliferation of c-Myc-overexpressing MB cell lines: AKAP12 (A-kinase anchor protein), CSNK1α1 (casein kinase 1, alpha 1), EPHA7 (EPH receptor A7) and PCTK1 (PCTAIRE protein kinase 1). When using RNAi and a pharmacological inhibitor selective for PCTK1, we could show that this kinase plays a crucial role in the proliferation of MB cell lines and the activation of the mammalian target of rapamycin (mTOR) pathway. In addition, pharmacological PCTK1 inhibition reduced the expression levels of c-Myc. Finally, targeting PCTK1 selectively impaired the tumor growth of c-Myc-overexpressing MB cells in vivo. Together our data uncover a novel and crucial role for PCTK1 in the proliferation and survival of MB characterized by cMYC amplification. INTRODUCTION Medulloblastoma (MB), a tumor arising in the cerebellum or medulla is the most prevalent malignant brain tumor in children [1]. Current treatments including surgery, craniospinal radiotherapy and chemotherapy have improved survival rates, which nowadays are approximately 80% [2, 3]. Nevertheless, there are still numerous patients with poor prognosis and survivors suffer from diminished quality of life caused by the aggressive therapy [2]. The current classification system for medulloblastoma is based on morphology (histopathology), and include variants such as desmoplastic/nodular, MBEN (medulloblastoma with extensive nodularity), classic medulloblastoma, large cell, and anaplastic medulloblastoma [4, 5]. During the past few years, transcriptome-based, molecular studies on cohorts of MB have depicted this tumor not as a single disease, but as a cluster of individual molecular subgroups. Four subtypes have been proposed with distinct characteristics in terms of gene expression, mutational profiles, epidemiology, and prognosis: Wnt, Shh, Group 3, and Group 4 [3, 6-8]. The most aggressive MB subtype (Group 3), that consists of 'classical' medulloblastomas and partially of the large cells/anaplastic (LCA) tumors is associated with amplification in cMyc [4]. Current treatments fail to cure two thirds of patients in this particular group [8]. Thus, it remains of great interest to investigate which role c-Myc plays in the biology of MB. c-Myc, a potent and frequently deregulated
    Oncotarget 11/2014; 1. · 6.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Members of the highly conserved and ubiquitously expressed pleiotropic CK1 family play major regulatory roles in many cellular processes including DNA-processing and repair, proliferation, cytoskeleton dynamics, vesicular trafficking, apoptosis, and cell differentiation. As a consequence of cellular stress conditions, interaction of CK1 with the mitotic spindle is manifold increased pointing to regulatory functions at the mitotic checkpoint. Furthermore, CK1 is able to alter the activity of key proteins in signal transduction and signal integration molecules. In line with this notion, CK1 is tightly connected to the regulation and degradation of β-catenin, p53, and MDM2. Considering the importance of CK1 for accurate cell division and regulation of tumor suppressor functions, it is not surprising that mutations and alterations in the expression and/or activity of CK1 isoforms are often detected in various tumor entities including cancer of the kidney, choriocarcinomas, breast carcinomas, oral cancer, adenocarcinomas of the pancreas, and ovarian cancer. Therefore, scientific effort has enormously increased (i) to understand the regulation of CK1 and its involvement in tumorigenesis- and tumor progression-related signal transduction pathways and (ii) to develop CK1-specific inhibitors for the use in personalized therapy concepts. In this review, we summarize the current knowledge regarding CK1 regulation, function, and interaction with cellular proteins playing central roles in cellular stress-responses and carcinogenesis.
    Frontiers in oncology. 01/2014; 4:96.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Isoforms of the casein kinase 1 (CK1) family have been shown to phosphorylate key regulatory molecules involved in cell cycle, transcription and translation, the structure of the cytoskeleton, cell-cell adhesion and receptor-coupled signal transduction. They regulate key signaling pathways known to be critically involved in tumor progression. Recent results point to an altered expression or activity of different CK1 isoforms in tumor cells. This review summarizes the expression and biological function of CK1 family members in normal and malignant cells and the evidence obtained so far about their role in tumorigenesis.
    Molecular Cancer 10/2014; 13(1):231. · 5.40 Impact Factor